P. Bradford

发表

Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene

G. Peirano, S. Ichiyama, Y. Matsumura, 2016, Emerging infectious diseases.

β-Lactams and β-Lactamase Inhibitors: An Overview.

K. Bush, P. Bradford, 2016, Cold Spring Harbor perspectives in medicine.

AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

P. Bradford, D. Keeney, A. Ruzin, 2007, The Journal of antimicrobial chemotherapy.

Global Incidence of Carbapenemase-Producing Escherichia coli ST131

G. Peirano, K. Kazmierczak, M. Hackel, 2014, Emerging infectious diseases.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

K. Kazmierczak, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

Use of Ribotyping To Retrospectively Identify Methicillin-Resistant Staphylococcus aureus Isolates from Phase 3 Clinical Trials for Tigecycline That Are Genotypically Related to Community-Associated Isolates

J. O'Connell, P. Bradford, B. Kreiswirth, 2005, Antimicrobial Agents and Chemotherapy.

Importance of Clonal Complex 258 and IncFK2-like Plasmids among a Global Collection of Klebsiella pneumoniae with blaKPC

G. Peirano, K. Kazmierczak, J. Pitout, 2017, Antimicrobial Agents and Chemotherapy.

Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

P. Bradford, 2001, Clinical Microbiology Reviews.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

K. Kazmierczak, M. Hackel, P. Bradford, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

K. Kazmierczak, P. Bradford, D. Sahm, 2015, Antimicrobial Agents and Chemotherapy.

Recent Developments in β-Lactamases and Inhibitors

T. Mansour, P. Bradford, A. Venkatesan, 2008 .

Establishment of In Vitro Susceptibility Testing Methodologies and Comparative Activities of Piperacillin in Combination with the Penem β-Lactamase Inhibitor BLI-489

T. Mansour, P. Bradford, S. Projan, 2008, Antimicrobial Agents and Chemotherapy.

Late stage antibacterial drugs in the clinical pipeline.

P. Bradford, S. Projan, 2007, Current opinion in microbiology.

β-Lactamases: Historical Perspectives

K. Bush, P. Bradford, 2007 .

Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical Isolates

P. Bradford, P. Petersen, 2005, Antimicrobial Agents and Chemotherapy.

Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate

K. Bush, P. Bradford, B. Rasmussen, 1994, Antimicrobial Agents and Chemotherapy.

SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients

K. Bush, A. Jaiswal, P. Bradford, 1995, Antimicrobial agents and chemotherapy.

SHV-7, a Novel Cefotaxime-Hydrolyzing β-Lactamase, Identified in Escherichia coli Isolates from Hospitalized Nursing Home Patients

K. Bush, A. Jaiswal, P. Bradford, 1995 .

Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Isolates Producing TEM-10 and TEM-43 β-Lactamases from St. Louis, Missouri

K. Bush, P. Bradford, Youjun Yang, 1998, Antimicrobial Agents and Chemotherapy.

Clinical Characteristics and Molecular Epidemiology Associated with Imipenem-Resistant Klebsiella pneumoniae

K. Bush, P. Bradford, S. Projan, 1999 .

Automated Thermal Cycling Is Superior to Traditional Methods for Nucleotide Sequencing ofblaSHV Genes

P. Bradford, 1999, Antimicrobial Agents and Chemotherapy.

Mannopeptimycins, New Cyclic Glycopeptide Antibiotics Produced by Streptomyces hygroscopicus LL-AC98: Antibacterial and Mechanistic Activities

P. Bradford, P. Petersen, E. Lenoy, 2003, Antimicrobial Agents and Chemotherapy.

Mechanism of Action of the Mannopeptimycins, a Novel Class of Glycopeptide Antibiotics Active against Vancomycin-Resistant Gram-Positive Bacteria

P. Bradford, Youjun Yang, A. Severin, 2004, Antimicrobial Agents and Chemotherapy.

Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria.

S. Lang, Nancy Torres, T. Mansour, 2004, Journal of medicinal chemistry.

Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin α, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates

P. Bradford, P. Petersen, R. Dushin, 2004, Antimicrobial Agents and Chemotherapy.

Identification and Analysis of Bacterial Protein Secretion Inhibitors Utilizing a SecA-LacZ Reporter Fusion System

L. Barbieri, B. Feld, W. Hu, 2000, Antimicrobial Agents and Chemotherapy.

Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities.

P. Bradford, James R. Johnson, S. Segal-Maurer, 2010, Diagnostic microbiology and infectious disease.

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing

M. Huband, P. Bradford, G. Stone, 2018, Antimicrobial Agents and Chemotherapy.

Characterization of expanded-spectrum cephalosporin resistance in E. coli isolates associated with bovine calf diarrhoeal disease.

I. Fingerman, P. Bradford, P. Petersen, 1999, The Journal of antimicrobial chemotherapy.

Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis

P. Bradford, R. Schuch, A. Watson, 2019, Antimicrobial Agents and Chemotherapy.

Cell wall active antifungal compounds produced by the marine fungus Hypoxylon oceanicum LL-15G256. III. Biological properties of 15G256 gamma.

S. Silverman, E. Sieverding, P. Bradford, 1998, The Journal of antibiotics.

and K the foss of an outer membrane protein . plasmid-mediated AmpC beta-lactamase , and is associated with the combination of ACT-1 , a Imipenem resistance in Klebsiella pneumoniae

Bush, P. Bradford, S. Projan, 1997 .

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections

P. Bradford, G. Stone, P. Newell, 2018, Antimicrobial Agents and Chemotherapy.

b -Lactams and b -Lactamase Inhibitors: An Overview

K. Bush, P. Bradford, 2016 .

In Vitro Activity of Tigecycline against Staphylococcus epidermidis Growing in an Adherent-Cell Biofilm Model

P. Bradford, P. Petersen, Pornpen Labthavikul, 2003, Antimicrobial Agents and Chemotherapy.

Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008–2014

M. Adams, G. Peirano, Y. Matsumura, 2018, Emerging infectious diseases.

Functional, Biophysical, and Structural Bases for Antibacterial Activity of Tigecycline

T. Rush, J. O'Connell, E. Feyfant, 2006, Antimicrobial Agents and Chemotherapy.

In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria

G. Basarab, M. Huband, P. Miller, 2014, Antimicrobial Agents and Chemotherapy.

Uses of Staphylococcus aureus GeneChips in Genotyping and Genetic Composition Analysis

E. Marsilio, F. Tenover, L. Mcdougal, 2004, Journal of Clinical Microbiology.

Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.

P. Bradford, R. Alm, W. Nichols, 2016, The Journal of antimicrobial chemotherapy.

In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.

P. Bradford, P. Petersen, C. H. Jones, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.

P. Bradford, P. Petersen, D. T. Weaver-Sands, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method

J. O'Connell, P. Bradford, M. Young, 2005, Antimicrobial Agents and Chemotherapy.

Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1

C. Dean, P. Bradford, S. Projan, 2003, Antimicrobial Agents and Chemotherapy.

What’s new in β-lactamases?

P. Bradford, 2001 .

The primary pharmacology of ceftazidime/avibactam: in vitro translational biology.

P. Bradford, G. Stone, W. Nichols, 2022, The Journal of antimicrobial chemotherapy.

Further Evidence that a Cell Wall Precursor [C55-MurNAc-(Peptide)-GlcNAc] Serves as an Acceptor in a Sorting Reaction

M. Siegel, P. Bradford, S. Projan, 2002, Journal of bacteriology.

Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug resistant isolates.

P. Bradford, Alita A. Miller, J. O’Donnell, 2020, ACS infectious diseases.

AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilis

P. Bradford, S. Projan, E. Murphy, 2003, Antimicrobial Agents and Chemotherapy.

Identification of Plasmid-Mediated AmpC -Lactamases in Escherichia coli, Klebsiella spp., and Proteus Species Can Potentially Improve Reporting of Cephalosporin Susceptibility Testing Results

R. Bonomo, J. Mcgowan, F. Tenover, 2009 .

Penicillin-binding proteins and induction of AmpC beta-lactamase

K. Bush, K. Young, P. Bradford, 1997, Antimicrobial agents and chemotherapy.

Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria.

P. Youngman, M. Hickey, D. Rothstein, 2002, The Journal of antibiotics.

Missouri -Lactamases from St. Louis, β and TEM-43 TEM-10 and Escherichia coli Isolates Producing Ceftazidime-Resistant Klebsiella pneumoniae

P. Bradford, D. Sahm, N. Bhachech, 2013 .

Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics

P. Bradford, C. Sanders, 1995, Antimicrobial agents and chemotherapy.

hospitalized nursing home beta-lactamase , identified in Escherichia coli SHV-7 , a novel cefotaxime-hydrolyzing

A. Jaiswal, P. Bradford, S. Projan, 1995 .

Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences

J. Quinn, R. Weinstein, K. Bush, 1993, Antimicrobial Agents and Chemotherapy.

antibiotics.for evaluation of new beta-lactam expressed in a common Escherichia coli host Development of test panel of beta-lactamases

P. Bradford, C. Sanders, 2013 .

Occurrence of Tetracycline Resistance Genes among Escherichia coli Isolates from the Phase 3 Clinical Trials for Tigecycline

A. Howe, M. Orlowski, P. Bradford, 2007, Antimicrobial Agents and Chemotherapy.

Genomic characterization of IMP and VIM carbapenemase-encoding transferable plasmids of Enterobacteriaceae

G. Peirano, Y. Matsumura, R. Devinney, 2018, The Journal of antimicrobial chemotherapy.

TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases

K. Bush, P. Bradford, N. Jacobus, 1996, Antimicrobial agents and chemotherapy.

Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection.

P. Bradford, D. Landman, J. Quale, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus.

P. Bradford, J. Etienne, S. Projan, 2003, Biochimica et biophysica acta.

In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens

P. Bradford, S. Projan, P. Petersen, 2002, Antimicrobial Agents and Chemotherapy.

In Vitro and In Vivo Activities of Novel 6-Methylidene Penems as β-Lactamase Inhibitors

J. O'Connell, T. Mansour, P. Bradford, 2004, Antimicrobial Agents and Chemotherapy.

Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection

M. Castanheira, P. Bradford, P. Simner, 2021, JAC-antimicrobial resistance.

Resistance of Gram-Negative Bacilli to Antimicrobials

C. Dean, P. Bradford, 2008 .

Identification and Sequence of a tet(M) Tetracycline Resistance Determinant Homologue in Clinical Isolates of Escherichia coli

P. Bradford, E. Murphy, M. Tuckman, 2006, Journal of bacteriology.

Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein

K. Bush, P. Bradford, S. Projan, 1997, Antimicrobial agents and chemotherapy.

Ceftriaxone-resistant salmonella infection acquired by a child from cattle.

P. Fey, M. Rupp, S. Hinrichs, 2000, The New England journal of medicine.

Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.

A. Eakin, Renu Singh, P. Bradford, 2015, The Journal of antimicrobial chemotherapy.

Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest

Anette Engelhardt, A. Bolmström, P. Bradford, 2007, Journal of Clinical Microbiology.

Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

P. Bradford, 2001, Clinical Microbiology Reviews.

Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam

P. Bradford, C. Sanders, 1993, Antimicrobial Agents and Chemotherapy.

Recurrent episodes of shock-like syndrome caused by the same strain of vancomycin-resistant Enterococcus faecium in a pediatric patient.

L. Papp, P. Bradford, S. Projan, 2003, Microbial drug resistance.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

K. Kazmierczak, M. Hackel, P. Bradford, 2016, Antimicrobial Agents and Chemotherapy.

Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.

P. Bradford, C. Urban, J. Rahal, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

P. Bradford, D. Landman, J. Quale, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Real-Time PCR and Statistical Analyses of acrAB and ramA Expression in Clinical Isolates of Klebsiella pneumoniae

P. Bradford, A. Ruzin, F. Immermann, 2008, Antimicrobial Agents and Chemotherapy.

MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli.

P. Bradford, E. Murphy, D. Keeney, 2007, The Journal of antimicrobial chemotherapy.

RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.

P. Bradford, D. Keeney, A. Ruzin, 2007, Microbial drug resistance.

Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae

P. Bradford, D. Keeney, A. Ruzin, 2005, Antimicrobial Agents and Chemotherapy.

The primary pharmacology of ceftazidime/avibactam: resistance in vitro.

P. Bradford, G. Stone, W. Nichols, 2023, The Journal of antimicrobial chemotherapy.

Pyrosequencing Using the Single-Nucleotide Polymorphism Protocol for Rapid Determination of TEM- and SHV-Type Extended-Spectrum β-Lactamases in Clinical Isolates and Identification of the Novel β-Lactamase Genes blaSHV-48, blaSHV-105, and blaTEM-155

P. Bradford, P. Petersen, A. Ruzin, 2008, Antimicrobial Agents and Chemotherapy.

Identification of Plasmid-Mediated AmpC β-Lactamases in Escherichia coli, Klebsiella spp., and Proteus Species Can Potentially Improve Reporting of Cephalosporin Susceptibility Testing Results

Robert A Bonomo, Fred C Tenover, Shannon L Emery, 2008, Journal of Clinical Microbiology.

Epidemiology of β-Lactamase-Producing Pathogens

K. Bush, P. Bradford, 2020, Clinical Microbiology Reviews.

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015

K. Kazmierczak, P. Bradford, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

CTX-M-5, a Novel Cefotaxime-Hydrolyzing β-Lactamase from an Outbreak of Salmonella typhimuriumin Latvia

G. Storch, P. Bradford, Youjun Yang, 1998, Antimicrobial Agents and Chemotherapy.

Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

R A Weinstein, J. Quinn, R. Weinstein, 1999, JAMA.

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

P. Bradford, D. Hoban, T. Stevens, 2005, Diagnostic microbiology and infectious disease.

Interplay between β-lactamases and new β-lactamase inhibitors

K. Bush, P. Bradford, Patricia A. Bradford, 2019, Nature Reviews Microbiology.

Tigecycline: a first in class glycylcycline

P. Bradford, 2004 .

Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002.

P. Bradford, D. Hoban, S. Bouchillon, 2004, International journal of antimicrobial agents.

A Novel MATE Family Efflux Pump Contributes to the Reduced Susceptibility of Laboratory-Derived Staphylococcus aureus Mutants to Tigecycline

P. Bradford, S. Projan, E. Murphy, 2005, Antimicrobial Agents and Chemotherapy.

Interplay between β-lactamases and new β-lactamase inhibitors

K. Bush, P. Bradford, 2019, Nature Reviews Microbiology.

RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

P. Bradford, A. Ruzin, F. Immermann, 2010, Microbial drug resistance.

AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganii

P. Bradford, D. Keeney, A. Ruzin, 2005, Antimicrobial Agents and Chemotherapy.

In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

P. Bradford, P. Petersen, P. Labthavikul, 2006, The Journal of antimicrobial chemotherapy.

Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections

A. Howe, M. Orlowski, P. Bradford, 2006, Antimicrobial Agents and Chemotherapy.

Characterization and Sequence Analysis of Extended-Spectrum-β-Lactamase-Encoding Genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates Collected during Tigecycline Phase 3 Clinical Trials

P. Bradford, D. Keeney, A. Ruzin, 2008, Antimicrobial Agents and Chemotherapy.

The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).

P. Bradford, G. Stone, W. Nichols, 2022, The Journal of antimicrobial chemotherapy.

Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets

Mariana Castanheira, M. Castanheira, P. Bradford, 2017, Antimicrobial Agents and Chemotherapy.

Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli

A. Kasarskis, R. Sebra, G. Peirano, 2017, Scientific Reports.

Epidemiology of Bacterial Resistance

P. Bradford, 2018 .

A Standard Numbering Scheme for Class C β-Lactamases

J. Frère, A. Oliver, D. Haft, 2019, Antimicrobial Agents and Chemotherapy.

Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam

P. Bradford, C. Sanders, 1992, Antimicrobial Agents and Chemotherapy.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

M. Castanheira, P. Bradford, R. Mendes, 2018, International journal of antimicrobial agents.

Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam

P. Bradford, C. Sanders, 1993, Antimicrobial Agents and Chemotherapy.

A Standard Numbering Scheme for Class C (cid:2) -Lactamases

J. Frère, A. Oliver, D. Haft, 2021 .

Antibiotics—From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it

P. Bradford, D. Shlaes, 2018, Pathogens & immunity.

Efficacy of Piperacillin Combined with the Penem β-Lactamase Inhibitor BLI-489 in Murine Models of Systemic Infection

P. Bradford, P. Petersen, A. Venkatesan, 2009, Antimicrobial Agents and Chemotherapy.

Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need.

V. Miriagou, R. Bonomo, G. Jacoby, 2009, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens

P. Bradford, G. Stone, P. Newell, 2016, Antimicrobial Agents and Chemotherapy.

Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893

D. Tabor, T. Slidel, H. Jafri, 2016, Antimicrobial Agents and Chemotherapy.

In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018

P. Bradford, F. Hu, Yan Guo, 2020, European Journal of Clinical Microbiology & Infectious Diseases.

In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018

P. Bradford, F. Hu, Yan Guo, 2020, European Journal of Clinical Microbiology & Infectious Diseases.

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial

P. Bradford, J. Chow, G. Stone, 2020, Antimicrobial Agents and Chemotherapy.

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.

M. Hackel, P. Bradford, Qiwen Yang, 2020, The Journal of antimicrobial chemotherapy.

Comment on: Resistance gene naming and numbering: is it a new gene or not?

D. Haft, A. Prasad, R. Bonomo, 2016, The Journal of antimicrobial chemotherapy.

Surveillance and Detection of Inhibitor-Resistant Beta-Lactamases in Clinical Isolates of Escherichia coli

P. Bradford, C. Urban, Joseph M. Villarin, 2017 .

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program

K. Kazmierczak, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

Genomic epidemiology of global VIM-producing Enterobacteriaceae

M. Adams, G. Peirano, Y. Matsumura, 2017, The Journal of antimicrobial chemotherapy.

The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.

P. Bradford, G. Stone, W. Nichols, 2023, The Journal of antimicrobial chemotherapy.

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

M. Huband, P. Bradford, M. Traczewski, 2019, Journal of Clinical Microbiology.

In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth.

P. Bradford, P. Petersen, C. Jones, 2007, Diagnostic microbiology and infectious disease.

A-101 Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen- Reducing Agent May Be Required in The Absence of Fresh Media

John L. Johnson, P. Bradford, D. Hoban, 2004 .

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

M. Huband, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

#AMRrounds: a systematic educational approach for navigating bench to bedside antimicrobial resistance

P. Bradford, S. Aitken, W. F. Wright, 2023, JAC-antimicrobial resistance.

In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

K. Kazmierczak, P. Bradford, D. Sahm, 2015, Antimicrobial Agents and Chemotherapy.

Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae.

K. Bush, P. Bradford, S. Projan, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli

A. Kasarskis, R. Sebra, G. Peirano, 2017, bioRxiv.

Identification of Plasmid-Mediated AmpC β-Lactamases in Escherichia coli, Klebsiella spp., and Proteus Species Can Potentially Improve Reporting of Cephalosporin Susceptibility Testing Results

R. Bonomo, J. Mcgowan, F. Tenover, 2008, Journal of Clinical Microbiology.

Identification of Plasmid-Mediated AmpC -Lactamases in Escherichia coli, Klebsiella spp., and Proteus Species Can Potentially Improve Reporting of Cephalosporin Susceptibility Testing Results

F. Tenover, P. Bradford, C. Spiegel, 2009 .

In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections

P. Bradford, G. Stone, P. Newell, 2017, The Journal of antimicrobial chemotherapy.

P. Bradford, G. Stone, P. Newell, 2016, Antimicrobial Agents and Chemotherapy.